Article Text

other Versions

PDF
Research paper
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
  1. Douglas S Goodin1,
  2. Anthony Traboulsee2,
  3. Volker Knappertz3,4,
  4. Anthony T Reder5,
  5. David Li2,
  6. Dawn Langdon6,
  7. Christian Wolf7,
  8. Karola Beckmann3,
  9. Andreas Konieczny8,
  10. George C Ebers9,
  11. for the 16-Year Long Term Follow-up Study Investigators
  1. 1University of California, San Francisco, California, USA
  2. 2University of British Columbia, Vancouver, British Columbia, Canada
  3. 3Bayer HealthCare, Montville, New Jersey, USA, Berlin, Germany
  4. 4Heinrich-Heine-Universität, Düsseldorf, Germany
  5. 5Department of Neurology, University of Chicago, Chicago, Illinois, USA
  6. 6Department of Psychology, Royal Holloway, Egham, Surrey, UK
  7. 7Lycalis, Bruxelles, Brussels, Belgium
  8. 8Lampe Konieczny and Company, Berlin, Germany
  9. 9University Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK
  1. Correspondence to Professor D S Goodin, University of California, San Francisco, 505 Parnassus Ave, Rm 794M, San Francisco, CA 94143-0114, USA; douglas.goodin{at}ucsf.edu

Abstract

Background Evaluating the long term benefit of therapy in multiple sclerosis (MS) is challenging. Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established.

Methods In a patient cohort from the pivotal interferon β-1b trial, the value of clinical and MRI measures were analysed, both at baseline and during the RCT, for predicting long term physical and cognitive outcome.

Results Baseline disability correlated with both physical (R2=0.22; p<0.0001) and cognitive (R2=0.12; p<0.0001) outcome after 16 years. Accrual of disability during the RCT (R2=0.12; p<0.0001) and annualised relapse rates during the trial correlated with physical outcome (R2=0.12; p<0.0001) but not with cognition. In contrast, baseline MRI measures of atrophy and lesion burden correlated with cognitive (R2=0.21; p<0.0001), but not with physical, outcome. Accumulation of plaque burden measured by MRI did not correlate with late physical disability or with cognitive outcome. Multivariate regression analysis using stepwise elimination demonstrated that baseline variables contributed independently to predicting long term outcomes while trial outcome variables contributed little. Overall, and considerably dependent on baseline measures, the models developed by this method accounted for approximately half of the variance in long term cognitive and disability outcome.

Conclusions Although on-trial change in some short term clinical measures correlated with long term physical and disability outcomes, the proportion of the variance explained by single commonly employed on-study variables was often small or undetectable. Better correlations were observed for several baseline measures, suggesting that long term outcome in MS may be largely determined early in the disease course.

Trial registration number http://Clinical Trials.gov, study registration NCT00206635.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding The study was sponsored by Bayer HealthCare Pharmaceuticals. PAREXEL MMS received payment from Bayer HealthCare Pharmaceuticals for editorial support.

  • Competing interests DSG, GE, AR, DLi, DL, AK, CW, VK and KB have support from Bayer HealthCare for the submitted work, AT has a specified relationship with Bayer HealthCare and might have an interest in submitted work from the previous 3 years. Both the sponsors and the independent investigators were intimately involved in the study design. The researchers DSG, GE, AR, DLi, AT and DL were independent of the funders. The researchers AK, CW, VK and KB either work or previously worked for the funders.

  • Ethics approval The study obtained ethics approval from the institutional review boards or independent ethics committees of the participating centres before long term follow-up planning, which began in 2004.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Statistical and data tables are available from the corresponding author (douglas.goodin{at}ucsf.edu). Participants gave written informed consent for data acquisition and data sharing.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.